Login to Your Account

Study Says Amgen's Denosumab Beats Fosamax in Bone Density

By Donna Young

Wednesday, May 21, 2008
Preliminary results of a Phase III study showed that Amgen Inc.'s osteoporosis drug denosumab significantly increased bone-mineral density (BMD) at the total hip in postmenopausal women who switched from using Merck & Co.'s Fosamax (alendronate). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription